NDLI: Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Graham, Christopher N. Hechmati, Guy Fakih, Marwan G. Knox, Hediyyih N. Maglinte, Gregory A. Hjelmgren, Jonas Barber, Beth Schwartzberg, Lee S.
Description	Country affiliation: United States Author Affiliation: Graham CN ( a a RTI Health Solutions, Research Triangle Park , NC , USA.); Hechmati G ( b b Amgen GmbH , Zug , Switzerland.); Fakih MG ( c c City of Hope Comprehensive Cancer Center , Duarte , CA , USA.); Knox HN ( a a RTI Health Solutions, Research Triangle Park , NC , USA.); Maglinte GA ( d d Amgen, Inc. , Thousand Oaks , CA , USA.); Hjelmgren J ( b b Amgen GmbH , Zug , Switzerland.); Barber B ( d d Amgen, Inc. , Thousand Oaks , CA , USA.); Schwartzberg LS ( e e West Clinic , Memphis , TN , USA.)
Abstract	OBJECTIVE: To compare the costs of first-line treatment with panitumumab + FOLFOX in comparison to cetuximab + FOLFIRI among patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC) in the US. METHODS: A cost-minimization model was developed assuming similar treatment efficacy between both regimens. The model estimated the costs associated with drug acquisition, treatment administration frequency (every 2 weeks for panitumumab, weekly for cetuximab), and incidence of infusion reactions. Average anti-EGFR doses were calculated from the ASPECCT clinical trial, and average doses of chemotherapy regimens were based on product labels. Using the medical component of the consumer price index, adverse event costs were inflated to 2014 US dollars, and all other costs were reported in 2014 US dollars. The time horizon for the model was based on average first-line progression-free survival of a WT RAS patient, estimated from parametric survival analyses of PRIME clinical trial data. RESULTS: Relative to cetuximab + FOLFIRI in the first-line treatment of WT RAS mCRC, the cost-minimization model demonstrated lower projected drug acquisition, administration, and adverse event costs for patients who received panitumumab + FOLFOX. The overall cost per patient for first-line treatment was \$179,219 for panitumumab + FOLFOX vs \$202,344 for cetuximab + FOLFIRI, resulting in a per-patient saving of \$23,125 (11.4%) in favor of panitumumab + FOLFOX. CONCLUSIONS: From a value perspective, the cost-minimization model supports panitumumab + FOLFOX instead of cetuximab + FOLFIRI as the preferred first-line treatment of WT RAS mCRC patients requiring systemic therapy.
File Format	HTM / HTML
ISSN	13696998
Issue Number	8
Journal	Journal of Medical Economics
Volume Number	18
e-ISSN	1941837X
Language	English
Publisher	Taylor & Francis
Publisher Date	2015-01-01
Publisher Place	Great Britain (UK)
Access Restriction	Subscribed
Subject Keyword	Discipline Health Services Research
Content Type	Text
Resource Type	Article
Subject	Health Policy

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in